Core Insights - Cellectar Biosciences is advancing its lead product, iopofosine I-131, towards a Conditional Marketing Authorization (CMA) submission to the European Medicines Agency (EMA) in Q3 2026, targeting potential commercialization in 2027 for Waldenström Macroglobulinemia treatment [1][4] - The company has initiated a Phase 1b dose-finding study for CLR 125 in Triple Negative Breast Cancer (TNBC), with early data expected by mid-2026 [1][4] - Cellectar's financial results for 2025 show a significant reduction in net loss compared to 2024, indicating improved operational efficiency [5][9] Corporate Developments - The CMA submission for iopofosine I-131 will be supported by data from the CLOVER WaM study, which includes 12-month follow-up data on all patients and updated response rates [4] - The company received Breakthrough Therapy Designation from the FDA for iopofosine I-131 in relapsed/refractory WM, expanding its market potential [4] - CLR 125 has shown good tolerability in vivo with no signs of end-organ toxicity and has demonstrated tumor reduction in preclinical studies [4][10] Financial Performance - As of December 31, 2025, Cellectar reported cash and cash equivalents of $13.2 million, down from $23.3 million in 2024, which is expected to fund operations into Q3 2026 [9] - Research and Development (R&D) expenses decreased to approximately $11.5 million in 2025 from $26.1 million in 2024, primarily due to reduced activity in the CLOVER WaM clinical study [9] - General and Administrative (G&A) expenses also decreased to approximately $11.5 million in 2025 from $25.6 million in 2024, reflecting reduced pre-commercialization efforts [9] Product Pipeline - The product pipeline includes iopofosine I-131, which is being evaluated for multiple cancer indications, including relapsed or refractory multiple myeloma and CNS lymphoma [8] - CLR 125 is currently in a Phase 1b study for TNBC, with the primary endpoint to determine a recommended Phase 2 dose and evaluate safety and initial response [4][10] - Cellectar is also developing CLR 225, targeting solid tumors with significant unmet needs, such as pancreatic cancer [11]

Core Insights - Cellectar Biosciences announced promising interim results from the CLOVER-2 Phase 1b clinical study of iopofosine I 131, showing extended progression-free survival (PFS) and overall survival (OS) in pediatric patients with relapsed or refractory high-grade gliomas [1][3][4] Study Details - The CLOVER-2 trial involves children, adolescents, and young adults with relapsed or refractory pediatric high-grade gliomas, focusing on safety, tolerability, and therapeutic activity of iopofosine I 131 [10] - Patients in the study experienced an average PFS of 5.4 months and OS of 8.6 months, with those receiving additional dosing cycles showing even better outcomes [4][7] Patient Outcomes - Two case studies highlighted significant tumor volume reduction and extended survival in patients treated with iopofosine I 131, with one patient achieving a PFS of 10.9 months and ongoing survival exceeding 18 months [5][6] - The safety profile of iopofosine I 131 was consistent with previous data, showing no severe toxicities and manageable hematologic adverse events [7] Regulatory Designations - The FDA has granted iopofosine I 131 several designations, including Rare Pediatric Drug and Orphan Drug status, indicating its potential as a significant treatment option for pediatric high-grade gliomas [2][13] Company Overview - Cellectar Biosciences focuses on developing proprietary drugs for cancer treatment, leveraging its Phospholipid Drug Conjugate delivery platform to enhance efficacy and safety [11][12]

Financial Data and Key Metrics Changes - The company ended 2024 with cash and cash equivalents of $23.3 million, compared to $9.6 million as of December 31, 2023, indicating a significant increase in liquidity [20] - The net loss for the full year ended December 31, 2024, was $44.6 million or $1.22 per basic share, compared to a net loss of $42.8 million or $3.50 per basic and fully diluted share during 2023 [23] Business Line Data and Key Metrics Changes - Research and development expenses for the full year 2024 were approximately $26.1 million, a decrease from $27.3 million in the prior year, primarily due to the timing of expenditures for the WM Phase 2 study [20][21] - Selling, general and administrative expenses for the full year 2024 were $25.6 million, compared to $11.7 million in the prior year, driven by pre-commercialization initiatives [21] Market Data and Key Metrics Changes - The company highlighted the significant market potential for iopofosine in the relapsed/refractory setting, driven by its novel mechanism of action and fixed dosing regimen [12][13] Company Strategy and Development Direction - The company is focused on advancing its Alpha and Auger radioisotopes solid tumor programs and is evaluating non-dilutive funding opportunities [8] - A strategic restructuring was implemented to reduce headcount by approximately 60%, expected to drive annual savings of about $7.5 million [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential value of iopofosine for patients with relapsed/refractory Waldenstrom's macroglobulinemia, despite regulatory setbacks [10][11] - The company is optimistic about achieving rapid enrollment in upcoming studies due to strong interest from the healthcare community [60] Other Important Information - The company is preparing for Phase 1 studies for both CLR 121225 and CLR 121125 in the first half of 2025, with estimated costs for these studies around $4.5 million each [72] Q&A Session Summary Question: Does the NDA acceptance require data from the confirmatory study or just the CLOVER study? - The accelerated approval will require data from the additional study as well [56] Question: Can you share the timeline for patients to achieve and be evaluated for an MRR response? - The company anticipates approximately 24 months to full enrollment, with major response rate outcomes expected about one month after enrollment [62] Question: What would be the comparator in the study? - The study will have an investigator choice design with two comparators, one being rituximab monotherapy [66] Question: Does the cash runway include the cost for IND filings for CLR 121225 and 125? - Yes, the runway includes the cost for IND filings, which is relatively modest [71] Question: Why is pancreatic cancer chosen for CLR 121225? - The choice is based on significant market need and strong preclinical efficacy signals observed in animal models [90]